Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

The US Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase Ib multiple ascending dose (MAD) clinical study of ...

The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...

The FDA has lifted its hold and has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ...

YolTech's gene therapy is intended as a one-time life-long cure for patients living with PH1, which can lead to kidney ...

The Sacramento Democrat said the cuts would be devastating to not only her constituents but to millions of poor, elderly, disabled, and minor Americans who rely on Medicaid.

The stock makes the NASDAQ top percentage gainer list, currently trading at 2.7402, up 1.3702, gaining 100.0146% on volume of ...

The Netflix documentary “The Remarkable Life of Ibelin” tells Mats’ story, nearly 10 years after he passed away from a ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...